VRCA

News Verrica Posts Profit in Fiscal Q2

14d ago

Scanner Unusual buy pressure (6.4x avg, 74% up-volume, +11.9% / +0.64 intraday, above VWAP)

83d ago

SEC filing VRCA Reports $35.6M Revenue, $15.3M YCANTH Net, +130% YoY, 99% Unit Growth, Phase 3 Advances, Debt-Free, Cash to 2027

83d ago

News Prabowo Names Former Central Banker as Deputy Finance Minister

117d ago

News Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts

146d ago